MapLight Therapeutics (MPLT) EBITDA (2024 - 2025)
MapLight Therapeutics' (MPLT) quarterly EBITDA came in at -$79.8 million in Q4 2025, down 271.37% year-on-year from $46.6 million in Q4 2024, and down 171.3% quarter-over-quarter from -$29.4 million in Q3 2025.
MapLight Therapeutics (MPLT) EBITDA (2024 - 2025) Analysis & Trends
MapLight Therapeutics has disclosed EBITDA across 2 years of filings, most recently posting -$79.8 million for Q4 2025.
- EBITDA for Q4 2025 came in at -$79.8 million, down 271.37% year-over-year; the trailing twelve-month figure through Dec 2025 was -$149.1 million (changed N/A YoY), and the FY2025 annual result was -$161.5 million, down 108.67% from the prior year.
- EBITDA came in at -$79.8 million for Q4 2025 at MapLight Therapeutics, down from -$29.4 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$18.4 million in Q3 2024 to a low of -$79.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | MapLight Therapeutics | 248.88 Mn | 248.88 Mn | - | -79.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79.82 Mn |
| Sep 30, 2025 | -29.42 Mn |
| Dec 31, 2024 | -21.49 Mn |
| Sep 30, 2024 | -18.40 Mn |